The incorporation of artificial intelligence (AI) into the clinical management of necrotizing enterocolitis (NEC) represents a bold stride toward unraveling one of neonatology’s most perplexing and devastating diseases. NEC, a catastrophic intestinal condition primarily affecting preterm infants, has long challenged clinicians due to its rapid onset and complex etiology. AI promises to synergize vast clinical data, biological signals, and emerging biomarkers, potentially transforming NEC prediction, diagnosis, and therapeutic strategies. However, this transformative potential is tempered by profound challenges spanning technical, infrastructural, and ethical domains that currently impede the translation of AI algorithms from controlled environments to bustling neonatal intensive care units worldwide.
One of the foremost hurdles lies in the rarity and heterogeneity of NEC, which undermine efforts to develop robust AI models. Deep learning algorithms, a subset of machine learning (ML), thrive on massive, diverse datasets to discern intricate patterns and yield reliable predictions. In practice, NEC’s low incidence restricts access to such extensive datasets, often limiting researchers to small, single-center data collections. This restriction causes AI models to overfit, meaning they perform exceptionally well on their training data but fail to generalize to unseen patient populations. Without a remedy, these models risk remaining academic curiosities rather than practical tools in neonatology.
To mitigate overfitting, external validation becomes imperative. This process involves evaluating AI models on datasets originating from multiple, demographically varied institutions, ensuring that predictions remain accurate across diverse neonatal populations. Unfortunately, only a minority of NEC AI studies have undertaken this crucial step, leading to concerns about the generalizability and clinical utility of many proposed algorithms. The absence of multicenter data sharing and external validation thus threatens to relegate promising AI innovations to the realm of theoretical speculation, preventing meaningful clinical impact.
Equally challenging is the issue of clinical trust, a critical prerequisite for AI adoption in sensitive settings like neonatal care. Complex models, particularly neural networks, often act as so-called “black boxes,” providing risk scores without transparent reasoning. Healthcare providers, understandably reluctant to entrust vulnerable infants’ care to opaque algorithms, demand explainability and mechanistic insight. Emerging techniques such as SHAP (Shapley Additive exPlanations) values pave the way for interpretable AI, linking specific clinical features to risk predictions and thus fostering clinician confidence. However, this field remains nascent and requires further refinement to gain widespread acceptance.
Another practical limitation is the low positive predictive value of current AI models applied to NEC. Even state-of-the-art algorithms like XGBoost, when processing vast datasets with hundreds of thousands of data points, may only identify a small fraction of true positives, for example generating a positive flag rate as low as 1.3%. This low yield poses a significant problem: false-positive alerts can cascade into unnecessary interventions, including costly and invasive sepsis evaluations, prolonged fasting, and extended use of central lines—all of which carry inherent risks. Such unintended consequences exemplify the delicate balance between leveraging AI for early detection and avoiding iatrogenic harm.
The risk of automation bias further complicates clinical integration. Overreliance on AI flags may erode clinicians’ critical judgment, prompting treatment based solely on algorithmic outputs rather than holistic patient assessments. This shift not only threatens patient safety but could perpetuate unjustified clinical protocols in infants incorrectly labeled as high risk. Hence, AI must be framed as an adjunct—augmenting but never replacing the nuanced expertise of skilled neonatologists.
From a technological standpoint, the infrastructure demands of NEC AI systems are formidable. Some models utilize microbiota-based prediction, relying on DNA sequencing and advanced bioinformatics pipelines to capture the dynamic gut ecosystem’s influence on disease risk. Others depend on continuous physiological monitoring integrated seamlessly with electronic health record (EHR) systems to analyze real-time vital signs and clinical data. This level of integration requires robust computing frameworks, interoperable health IT infrastructures, and sophisticated data extraction and processing capabilities, all of which pose significant implementation challenges in resource-limited settings.
Building an AI model is merely the initial phase; maintaining its clinical fidelity over time demands dedicated Machine Learning Operations (MLOps). Neonatal environments are dynamic; patient demographics, clinical documentation practices, laboratory assays, and EHR configurations evolve continually. Without systematic MLOps—encompassing version control, continuous performance evaluation, bias monitoring, retraining protocols, and governance structures—AI models risk silent performance degradation, known as model drift. Ensuring long-term accuracy and safety thus hinges on establishing these operational frameworks alongside clinical deployment.
Despite these demands, no comprehensive cost-benefit analyses have rigorously evaluated whether the substantial infrastructure, training, and maintenance investments justify the anticipated gains from earlier NEC detection or improved neonatal outcomes. Future research, ideally employing rigorous real-world evidence methodologies endorsed by entities like the Observational Health Data Sciences and Informatics Evidence Network (OHDSI), must address this critical gap. Such studies will be pivotal in determining AI’s pragmatic role in NEC care pathways and securing stakeholder buy-in.
Ethics form an indispensable pillar in the integration of AI into neonatal medicine. AI models trained on historical datasets risk perpetuating embedded systemic biases related to race, socioeconomic status, or healthcare access disparities. Transparency in model development, validation, and ongoing monitoring is essential to uphold core principles of beneficence and non-maleficence. Currently, regulatory approval paths remain murky for AI-powered clinical decision support tools in neonatal contexts. Notably, no NEC prediction model has yet achieved clearance by the U.S. Food and Drug Administration or equivalent global regulators, underscoring the urgent need for clearer frameworks that balance innovation with safety and equity.
In summary, AI embodies a revolutionary frontier with the capacity to redefine NEC research and clinical care fundamentally. By disentangling the complex interplay of genetic susceptibilities, microbial ecology, physiological signals, and clinical indicators, AI can usher in a new era of precision neonatology. Yet, actualizing this vision mandates a concerted paradigm shift encompassing pooled multicenter data collaborations, robust external validations, comprehensive infrastructural investments, dedicated operational oversight, and unwavering ethical commitments.
As the neonatal care community embarks on this journey, collaborative partnerships among clinicians, data scientists, bioethicists, and health system leaders will be vital. Only by navigating the intricate technical, practical, and moral challenges through interdisciplinary synergy can AI fulfill its promise of reducing the morbidity and mortality associated with this devastating illness. With vigilant stewardship and patient-centered innovation, AI’s transformative potential in NEC may soon transition from visionary prospect to everyday clinical reality, heralding a future where precision interventions safeguard the most vulnerable lives.
Subject of Research: Artificial intelligence in the prediction and management of necrotizing enterocolitis (NEC)
Article Title: Emerging role of artificial intelligence in necrotizing enterocolitis and implementation challenges
Article References:
Krishnan, P., Gunasekaran, V., Hillegass, W.B. et al. Emerging role of artificial intelligence in necrotizing enterocolitis and implementation challenges. Pediatr Res (2026). https://doi.org/10.1038/s41390-026-05041-0
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41390-026-05041-0
Tags: AI algorithm generalizability issuesAI challenges in neonatologyAI-driven therapeutic strategies for NECartificial intelligence in necrotizing enterocolitisbiomarkers for NEC diagnosisclinical data integration in NECdata scarcity in medical AI researchdeep learning for neonatal diseasesethical issues in AI healthcare applicationsmachine learning limitations in rare diseasesnecrotizing enterocolitis prediction modelsneonatal intensive care AI implementation
